Literature DB >> 16422301

Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus.

Acacio Gonçalves Rodrigues1, Ricardo Araujo, Cidalia Pina-Vaz.   

Abstract

Invasive aspergillosis is one of the most common deep-seated fungal infections among patients with an impaired immune system. Albumin is a serum protein commonly administered to critical patients. Our objective was to evaluate the in vitro effect of human albumin upon germination and hyphal growth of Aspergillus species, especially the most pathogenic, Aspergillus fumigatus, as well as its influence on antifungal drug activity. Human albumin induced, at normal serum concentrations (2-4%), a significant promotion of conidial germination by A. fumigatus, but not by Aspergillus flavus and Aspergillus niger. However, mycelium growth following germination was enhanced in all Aspergillus species. Minimal inhibitory concentrations (MIC) of all strains tested to amphotericin B and itraconazole increased in the presence of physiological concentrations of human albumin. Voriconazole activity was not, however, significantly affected by the presence of the protein. Conidial germination represents a crucial initial step in the progression to invasive disease, involving metabolic pathways that may differ considerably among Aspergillus species. Our results support the concept that human albumin may promote a faster onset and enhanced dissemination of invasive aspergillosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16422301     DOI: 10.1080/13693780500129814

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  9 in total

Review 1.  Regulatory circuitry governing fungal development, drug resistance, and disease.

Authors:  Rebecca S Shapiro; Nicole Robbins; Leah E Cowen
Journal:  Microbiol Mol Biol Rev       Date:  2011-06       Impact factor: 11.056

2.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

Review 3.  Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis.

Authors:  Taylor R T Dagenais; Nancy P Keller
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

4.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

5.  Disparate proteome responses of pathogenic and nonpathogenic aspergilli to human serum measured by activity-based protein profiling (ABPP).

Authors:  Susan D Wiedner; Charles Ansong; Bobbie-Jo Webb-Robertson; LeeAnna M Pederson; Suereta Fortuin; Beth A Hofstad; Anil K Shukla; Ellen A Panisko; Richard D Smith; Aaron T Wright
Journal:  Mol Cell Proteomics       Date:  2013-04-18       Impact factor: 5.911

6.  Multiplexed activity-based protein profiling of the human pathogen Aspergillus fumigatus reveals large functional changes upon exposure to human serum.

Authors:  Susan D Wiedner; Kristin E Burnum; LeeAnna M Pederson; Lindsey N Anderson; Suereta Fortuin; Lacie M Chauvigné-Hines; Anil K Shukla; Charles Ansong; Ellen A Panisko; Richard D Smith; Aaron T Wright
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

7.  In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection.

Authors:  Thomas Colley; Alexandre Alanio; Steven L Kelly; Gurpreet Sehra; Yasuo Kizawa; Andrew G S Warrilow; Josie E Parker; Diane E Kelly; Genki Kimura; Lauren Anderson-Dring; Takahiro Nakaoki; Mihiro Sunose; Stuart Onions; Damien Crepin; Franz Lagasse; Matthew Crittall; Jonathan Shannon; Michael Cooke; Stéphane Bretagne; John King-Underwood; John Murray; Kazuhiro Ito; Pete Strong; Garth Rapeport
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 8.  Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.

Authors:  Sofia Costa-de-Oliveira; Acácio G Rodrigues
Journal:  Microorganisms       Date:  2020-01-22

9.  Albumin Neutralizes Hydrophobic Toxins and Modulates Candida albicans Pathogenicity.

Authors:  Sophie Austermeier; Marina Pekmezović; Pauline Porschitz; Sejeong Lee; Nessim Kichik; David L Moyes; Jemima Ho; Natalia K Kotowicz; Julian R Naglik; Bernhard Hube; Mark S Gresnigt
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.